Plasma metabolomics of primary open-angle glaucoma in three prospective US cohorts and the UK Biobank

Study Population - Nurses’ Health Study (NHS), NHSII and Health Professional Follow-up Study (HPFS)

We conducted a nested case-control study in the NHS, NHSII and HPFS cohorts from the US. The NHS was initiated in 1976 with 121,700 female registered nurses aged 30–55 years at enrollment; the NHSII began in 1989 with 116,429 female registered nurses aged 25-42 years, and the HPFS was launched in 1986 with 51,529 male health professionals aged 40–75 years. Participants have completed biennial questionnaires that asked about lifestyle and medical conditions, such as glaucoma. POAG cases were identified among participants who self-reported a physician diagnosis of glaucoma on biennial questionnaires. To confirm the self-reports of glaucoma, we asked participants for their consent to obtain relevant medical records from their treating providers. All eye care providers of record were requested to send all available visual fields (VFs) and were mailed a supplementary questionnaire to complete and return. A glaucoma specialist (LRP) reviewed the questionnaire (or medical records sent instead of questionnaires) as well as the VFs in a standardized manner. This questionnaire included items about untreated maximum IOP, any secondary causes of high untreated IOP, filtration angle, structural features of the optic nerve, glaucoma surgery, any VF loss and any secondary conditions that may cause VF loss. Cases we included in analyses had at least two reliable VFs (≤ 20% for false negative rate and false positive rate and ≤ 33% for fixation loss rate) that showed reproducible defects consistent with glaucoma, non-occludable angles in both eyes, and no secondary causes of IOP elevation (e.g., trauma, uveitis, exfoliation syndrome, pigment dispersion syndrome evident on biomicroscopic anterior segment examinations).

Blood samples were collected in 1989–’90 among 32,826 NHS participants, in 1996–’99 among 29,611 NHS2 participants and in 1993–’95 among 18,159 HPFS participants. Participants arranged to have samples drawn and shipped by overnight courier to the laboratory; with sample processing, white blood cell, red blood cell, and plasma aliquots were archived in liquid nitrogen freezers (≤-130^°C). POAG cases were diagnosed after blood draw until June 1, 2016 (NHS and NHS2), or January 1, 2016 (HPFS). Controls were 1:1 matched to cases on: age, cohort/sex, month and year of blood collection, time of day of blood draw, fasting status (> or ≤8 hours), race/ethnicity, and among women: additional matching on menopausal status and hormone therapy use at blood draw (premenopausal, postmenopausal and on hormone therapy (HT), postmenopausal and not on HT, missing/unknown) and at glaucoma diagnosis. For matching factors and covariates, we used questionnaire data collected as of the blood draw, and if not available, we used biennial questionnaire data prior to the blood sample. The study protocol was approved by the institutional review boards (IRBs) of the Brigham and Women’s Hospital, Harvard T.H. Chan School of Public Health, and Icahn School of Medicine at Mount Sinai. Completion of self-administered questionnaires and returns of blood samples were considered as implied consents by the IRBs. Medical record release consents were obtained for collection of medical records. This research study adhered to the tenets of the Declaration of Helsinki.

Study Population – UK Biobank

The UK Biobank is an ongoing population-based study initiated in 2006-2010 with over 500,000 participants aged 40-69 years. We used baseline questionnaire as well as metabolomic data (http://www.ukbiobank.ac.uk). The UK Biobank was approved by the National Information Governance Board for Health and Social Care and the National Health Service North West Multicenter Research Ethics Committee (reference number 06/MRE08/65). This research was conducted using the UK Biobank Resource under application number 36741.

At baseline (2006-2010), participants completed a touch screen questionnaire and were considered to have glaucoma if in response to the question, “Has a doctor told you that you have any of the following problems with your eyes?”, they chose glaucoma from the menu. Participants were also considered to have glaucoma if they reported a history of glaucoma surgery or laser on the questionnaire or if they carried an ICD9/10 code for glaucoma (ICD 9: 365.*; ICD10: H40.** (excluding H40.01* and H42.*)).

Metabolite profiling – NHS, NHSII, HPFS

As described previously,^10–12 plasma metabolites were profiled using liquid chromatography tandem mass spectrometry (LC-MS) to measure endogenous, polar metabolites and lipids (Broad Institute of MIT and Harvard University (Cambridge, MA)). Among 427 known metabolites, we excluded 60 that were impacted by delayed blood processing,¹³ leaving 367 metabolites for analyses. For metabolites with <10% missing across participant samples, missing values were imputed with 1/2 of the minimum value measured for that metabolite as has been done in prior studies.¹⁴ All but one included metabolite exhibited good within person reproducibility over a 1-year period, indicating that one blood sample provides a reasonable measure of longer-term exposure (312 out of 313 available 1 year Pearson or intraclass correlations were >0.4).¹³ For 317 (out of 367) metabolites, they were each assigned a metabolite class (30 in total) based on chemical taxonomy; we evaluated 17 metabolite classes which included at least 3 metabolites: steroids and steroid derivatives; carnitines; diglycerides (DGs); triglycerides (TGs); cholesteryl esters; lysophosphatidylethanolamines (LPEs); phosphatidylethanolamines (PEs); lysophosphatidylcholines (LPCs); phosphatidylcholines (PCs); phosphatidylcholine plasmalogens; phosphatidylethanolamines plasmalogens; organoheterocyclic compounds; ceramides; carboxylic acids and derivatives; organic acids and derivatives; nucleosides, nucleotides, and analogues; and sphingomyelins. Metabolite values were transformed to probit scores to scale to the same range and to minimize the influence of skewed distributions.

Metabolite profiling – UK Biobank

In the UK Biobank, non-fasting baseline plasma samples from a random subset of 119,764 participants (118,466 individuals’ samples collected at baseline and 1298 individuals’ samples collected during repeat-visits) were assessed using targeted high-throughput NMR metabolomics (Nightingale Health Ltd; Helsinki, Finland).¹⁵ In contrast to LC/MS, in ¹H NMR spectroscopy, molecules with H atoms yield distinctive spectral shapes with areas under their curves proportional to the molecules’ concentration based on chemical shifts and J coupling splitting patterns determined from quantum mechanics,^{16, 17} thus allowing for detailed quantification. The platform provided quantification of 249 metabolic measures including routine clinical lipids (37 biomarkers in the panel have been certified for diagnostic use), lipoprotein subclasses, fatty acid composition, and several low-molecular weight metabolites such as glycolysis metabolites, ketone bodies and amino acids measured in molar concentration units. Of the 249 measures, we focused on 168 measures that were concentrations of various metabolites (and the 81 remaining measures such as ratios between metabolites, percentages of individual metabolites of total classes or degree of unsaturation were excluded).

Statistical analysis

Study population

Among 599 cases, 74.3% were female, with a mean (SD) age at blood draw of 58.0 (SD=8.0) years and at diagnosis of 68.3 (SD=9.2) years. Mean time between blood draw to diagnosis was 10.3 years. Controls were similar to cases for the matching factors. Distributions of POAG risk factors were generally in the expected directions for cases and controls (Table 1).

Relation between individual metabolites and POAG

Supplementary Table S1 presents the individual associations between the 367 metabolites and POAG; 6 metabolites that were at least nominally significant at p<0.05 in any of the models (Model 1 through Model 5) are plotted in Figure 1. In Model 1 (model incorporating matching) results, all 6 metabolites were nominally significant, including two diglycerides (DG(36:2), DG(34:1)), one triglyceride (TG(52:2)), two LPCs (LPC(16:0) and Na_LPC(16:0)) and one LPE(16:0); of these, LPE(16:0), TG(36:2), TG(52:2) and Na-LPC(16:0) were NEF-p<0.2. In successive models, the associations were generally similar, although the significance was attenuated with additional adjustment for covariates. In Model 2, where we more finely adjusted for matching factors (e.g., fasting status, time of day) and other major determinants of variability in metabolites, such as BMI, only the glycerides were NEF-p<0.2. However, in successive models of Model 3 and 4 (addition of POAG established and suspected risk factors), and Model 5 (further adjust for co-morbidities), we observed that while none of the metabolites were NEF<0.05, all were nominally significant and the direction of associations for the metabolites was similar.

• Download figure
• Open in new tab

Figure 1. Individual metabolites among the n=367 metabolites evaluated that were significant across the various nested multiple conditional logistic regression models of primary open-angle glaucoma (599 cases and 599 controls).

Model 1: basic model, adjusting for matching factors only (see Table 1); Model 2 (factors that affect metabolite levels and matching factors as matching was imperfect): Model 1 + age, sex, smoking status, BMI, physical activity, time of day of blood draw, month of blood draw, fasting status; Model 3 (established risk factors for primary open-angle glaucoma (POAG)): Model 2 + family history of glaucoma, socioeconomic index based on census tract data, race/ethnicity and age at menopause; Model 4 (potential modifiable dietary risk factors for POAG): Model 3 + nitrate intake, caffeine intake, alcohol intake, caloric intake; Model 5 (systemic comorbidities / drugs suggested to be associated with POAG in some studies): Model 4 + hypertension, high cholesterol, diabetes and oral steroid use. * p<0.05; ** Number of effective tests (NEF)<0.2; *** NEF<0.05

Relation between metabolite classes and POAG

Figure 2 shows the results of evaluating metabolite classes and POAG; results for all 17 metabolite classes are plotted. Model 1 showed 9 classes that were associated: 6 lipid metabolite classes of triglycerides, LPCs, diglycerides, LPEs, PCs, and PEs were FDR-significantly associated with POAG risk, while cholesteryl esters, carnitines and organic acids and derivatives (which includes amino acids) were inversely associated with POAG risk. In Model 2, results were similar, although among lipids, for phosphatidylethanolamines, the FDR was ≥0.2. Similarly, Models 3, 4 and 5, with the addition of POAG risk factors in models, the adverse associations with LPCs, LPEs, and diglycerides (in Model 5) and the inverse associations with cholesteryl esters and organic acids and derivatives (which includes amino acids) were robust and FDR-significant. For carnitines and phosphatidylethanolamines, the FDR was ≥0.2 and for PCs and triglycerides, the FDR was <0.2; interestingly, in Model 5, an inverse association with sphingomyelins was observed at FDR<0.2.

Relation between metabolite classes and POAG subtypes defined by visual field loss patterns

POAG is multifactorial and clinically heterogeneous. Investigating heterogeneity in VF loss patterns for POAG may provide new etiologic insights as different types of optic nerve damage manifest as distinct VF loss patterns. For example, glaucomatous paracentral scotomas have been associated with more systemic risk factors compared to peripheral VF loss.^24–26 Therefore, we separately evaluated the associations between metabolite classes and POAG defined by VF loss patterns (paracentral (Figure 3a; n=178 cases) versus peripheral VF loss (Figure 3b; n=331 cases)); of the 599 cases, VF loss pattern derived from Humphrey visual field test were available in 509 cases. As shown in Figure 3a and Figure 3b, overall, more metabolite classes (9 classes versus 5 classes) were significantly associated with POAG with paracentral VF loss versus peripheral VF loss. In addition to the three classes associated with peripheral VF loss - namely diglycerides, LPCs, and LPEs - for POAG with paracentral VF loss, the classes of triglycerides, PEs, and PCs were also adversely associated at FDR<0.05. In addition to cholesteryl esters and organic acids and derivatives being inversely associated with POAG with peripheral VF loss, the class of carnitines was also inversely associated with POAG with paracentral VF loss at FDR<0.05.

• Download figure
• Open in new tab

Figure 2. Metabolite classes (n=17) evaluated in various nested multiple conditional logistic regression models of primary open-angle glaucoma (POAG; 599 cases and 599 controls).

Model 1: basic model, adjusting for matching factors only (see Table 1); Model 2 (factors that affect metabolite levels and matching factors as matching was imperfect): Model 1 + age, sex, smoking status, BMI, physical activity, time of day of blood draw, month of blood draw, fasting status; Model 3 (established risk factors for primary open-angle glaucoma (POAG)): Model 2 + family history of glaucoma, socioeconomic index based on census tract data, race/ethnicity and age at menopause; Model 4 (potential modifiable dietary risk factors for POAG): Model 3 + nitrate intake, caffeine intake, alcohol intake, caloric intake; Model 5 (systemic comorbidities / drugs suggested to be associated with POAG in some studies): Model 4 + hypertension, high cholesterol, diabetes and oral steroid use. * False Discovery Rate (FDR)<0.2; ** FDR<0.05; *** FDR<0.001

• Download figure
• Open in new tab

Figure 3. Metabolite classes (n=17) evaluated in various nested multiple logistic regression models of POAG with paracentral visual field loss (178 cases and 599 controls) in panel A and POAG with peripheral visual field loss (331 cases and 599 controls) in panel B, in NHS/NHSII/HPFS.

Metabolite classes are plotted in the same as in the main analysis (Figure 2). Model 1: basic model, adjusting for matching factors only; Model 2 (factors that influence metabolites): age + smoking status + BMI + physical activity + time of day (as matching imperfect) + month of blood draw (season, as matching imperfect); Model 3 (established risk factors for POAG): M2 + family history of POAG + SES + race + age at menopause; Model 4 (established risk factors for POAG): M3 + nitrate intake + caffeine intake + alcohol intake + alternate healthy eating index + caloric intake; Model 5 (co-morbidities / drugs that have been associated with POAG): M4 + hypertension + high cholesterol + diabetes + oral/inhaled steroid use. * False Discover Rate (FDR)<0.2; ** FDR<0.05; *** FDR<0.001

Secondary analyses

Because prior studies of triglycerides in relation to health outcomes^{27, 28} have observed differing associations by the degree of saturation and number of carbon atoms, in exploratory analyses, we further plotted the associations as a function of the number of double bonds in triglycerides and the number of carbon atoms. Interestingly, as found with diabetes and cardiovascular disease,^{27, 28} in general, those triglycerides with fewer carbon atoms and double bonds were adversely associated with POAG risk while those with higher carbon atoms and double bonds were inversely associated with POAG risk (Figure 4).

• Download figure
• Open in new tab

Figure 4. POAG association pattern among triglycerides (TGs) in NHS/NHSII/HPFS (599 cases and 599 controls).

Results are shown by the number of carbon atoms (fatty acyl chain length) and double bonds (saturation) of each triglyceride. Each triglyceride is represented by a circle. The color of the circle correlates with the association direction (red: positive, blue: inverse) and the size of the circle corelates with the statistical significance (larger circles represent smaller p-values).

To evaluate whether associations differed by subgroups, in exploratory analyses, we assessed whether results varied by age (Supplementary Figure S1), sex (Supplementary Figure S2), BMI (Supplementary Figure S3), time to diagnosis (Supplementary Figure S4), and history of glaucoma (Supplementary Figure S5). Although no major differences were observed in various subgroups, there were some suggestions that the associations were strongest in those with BMI>25 kg/m² and those diagnosed within the decade after blood draw.

UK Biobank results

To assess whether the associations observed in NHS/NHS2/HPFS might also be observed in the UK Biobank, we conducted metabolomic analyses of the outcome of glaucoma, defined based on self-reported glaucoma, use of glaucoma medications and ICD codes (2238 glaucoma cases and 44723 non-cases). In general, glaucoma cases were older, had more diabetes, and higher systolic blood pressure (Table 2).

In multivariable-adjusted analyses of individual metabolites (Figure 5; Supplementary Table S2), we observed that 8 triglyceride metabolites as well as phospholipids (from which lysophospholipids are derived through hydrolysis) were nominally associated with higher glaucoma risk; tyrosine (NEF<0.05) and glucose (NEF<0.05) were significantly associated with higher glaucoma risk, while specific organic acids and derivatives, such as acetate, 2-hydroxybutyrate, citrate, pyruvate and lactate were inversely associated at NEF<0.05. (In NHS/NHS2/HPFS (Supplementary Table S1), tyrosine and valine were included as carboxylic acids and derivatives; glutamine and phenylalanine were included as organic acids and derivatives; however, glucose, acetate, 3-hydroxybutyrate, citrate, pyruvate and lactate data were not available).

• Download figure
• Open in new tab

Figure 5. Individual metabolites (out of N=168) that were nominally significantly associated with prevalent POAG in the UK Biobank (2238 cases, 44723 controls).

Multiple logistic regression model includes age, sex, smoking status, physical activity, BMI, ethnicity, spherical equivalent, coffee consumption, tea consumption, alcohol intake, systolic blood pressure, cholesterol level, diabetes, coronary artery disease, and statin use.

* p<0.05; ** Number of effective tests corrected p-value (NEF)<0.2; *** NEF<0.05

Triglycerides and cholesteryl esters

The relation between triglycerides and glaucoma has been conflicting, with studies showing an adverse association,⁴¹ inverse association⁴² and null association (Mendelian randomization study⁴³). A systematic review⁴⁴ of 12 studies reported a significantly higher risk of open-angle glaucoma with hyperlipidemia as well as hypertriglyceridemia (OR=1.42; 95%CI 1.04, 1.93; based on pooling of 4 studies). Our study confirmed this adverse association between higher triglycerides and POAG risk in two populations. This finding is consistent with the discovery of POAG loci near genes related to cholesterol metabolism (ABCA1 and CAV1/2). One biological mechanism for this association may be intraocular pressure-related: hypertriglyceridemia can lead to increased blood viscosity, which causes elevation of episcleral venous pressure^{45, 46} and higher IOP. Indeed, a review⁴⁴ reported that higher triglyceride level was significantly associated with modest increases of IOP. Interestingly, we observed that the relationship with triglycerides were complex. Triglycerides that are shorter and more saturated were adversely associated while those that are longer and are more unsaturated were inversely associated with POAG, possibly because such triglycerides may be markers of a healthier cardiometabolic profile.²⁸ Finally, triglycerides showed stronger associations with POAG with paracentral VF loss than that with peripheral loss, further underscoring the observation that this subtype is more strongly associated with systemic factors. As for cholesteryl esters, there is limited data in relation to glaucoma; however, it is known that the ratio of cholesterol to esterified cholesterol is altered with age and in several neurodegenerative diseases.⁴⁷

Phospholipids

We observed adverse associations between several phospholipid classes and POAG risk. PCs/PEs and their partial hydrolysis products, LPCs/LPEs, are implicated in aging^48–50 as well as type 2 diabetes⁵¹, and play key roles in mitochondrial dynamics.⁵² PEs and PCs are abundant membrane phospholipids that provide membrane structure and facilitate vacuolar delivery and cytokinesis. However, LPCs are pro-inflammatory and pro-oxidant,⁵³ and they may play a role in the autotaxin-lysophophatidic acid pathway in intraocular pressure regulation.^{35, 37, 54–57} Our results are consistent with other targeted lipidomic studies of glaucoma that have revealed higher specific phospholipids in blood,⁹ the trabecular meshwork or aqueous humor of glaucomatous eyes.^{55, 56, 58, 59}

Mitochondrial dysfunction, carnitines and organic acids and derivatives

Mitochondrial dysfunction has been hypothesized as a key component of POAG pathophysiology.^60–66 Plasma metabolomic markers of mitochondrial function may include acylcarnitines, which transport acyl-groups (organic acids and fatty acids) into the mitochondria so that they can be broken down to produce energy in a process known as beta-oxidation. In our study, POAG cases had lower levels of acylcarnitines, particularly the long-chain acylcarnitines. Interestingly, high-fructose diets were associated with a decrease in long-chain acylcarnitines, suggesting a decrease in mitochondrial β-oxidation and an increase in lipid peroxidation, which also led to higher triglycerides.⁶⁷ Carnitine has also been shown to be neuroprotective in a glaucoma animal model.⁶⁸ This is consistent with several cross-sectional studies of glaucoma that have also identified alterations in the carnitine pool.^{33, 35, 69}

Related to the importance of mitochondrial health, greater use as an energy source of ketone bodies, such as higher 3-hydroxybutyrate versus glucose may also be important. In the UK Biobank, a higher level of 3-hydroxybutyrate was inversely associated with POAG risk. Ketone bodies have been associated with greater mitochondrial efficiency and have neuroprotective properties.⁷⁰ This is consistent with a large genetic pathway analysis study that identified the butanoate pathway, which is involved in generating precursors for ketone bodies, as being important for POAG etiology, ⁷¹ a study that observed suggestive lower risk of POAG with paracentral VF loss with a plant-based low carbohydrate diet⁷² and another study analyzing genes encoding mitochondrial proteins that implicated lipid and carbohydrate metabolism as being important in POAG.⁷³

Among the most inversely associated organic acids and derivatives were N1-Acetylspermidine and N1,N12-Diacetylspermine (Supplementary Table S1). Spermine and spermidine are amines that also regulate mitochondrial membrane potential and have neuroprotective effects;³³ these metabolites have also been inversely associated with POAG in the study by Leruez et al.³³ Tyrosine is another that has been identified by Leruez et al.³³ and was found to be associated with glaucoma in the UK Biobank and thus warrants further study.

A limitation of our data is that our NHS/NHS2/HPFS study population was relatively homogeneous, with mostly White health professionals; therefore, our findings may not be generalizable to other populations with different race and ethnicity composition. Additionally, there may have been residual confounding by other unmeasured factors. A further potential limitation is that our blood samples were collected at one timepoint; However, we included only those metabolites with good correlations for within person stability over at least 1 year. In addition, the UK Biobank data was cross-sectional and included prevalent cases of glaucoma, who would have been comprised mostly of POAG cases, but may have also included those with other types of glaucoma, which would have led to biases due to disease misclassification. Also, there was the possibility in the UK Biobank that metabolite levels may have been influenced by glaucoma treatment; thus, our results need to be interpreted cautiously. However, the confirmation of the associations with triglycerides and phospholipids provided support to the prospective associations observed in NHS/NHS2/HPFS.

Our study had several strengths. To our knowledge, our study in NHS/NHS2/HPFS is the first study assessing the associations of pre-diagnostic metabolites collected ~ 10 years before diagnosis and POAG risk, with a relatively large sample size of 599 cases and 599 matched controls. Additional strengths include the detailed covariate information and long time between blood draw and diagnosis date (mean=10.3 years) and the availability of the UK Biobank data to confirm findings.

Overall, these results provide new insights into the etiology of POAG. Our data implicate dysregulation in lipid metabolism and mitochondrial function in glaucoma etiology and suggest new targets for glaucoma prevention or therapies.